These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11796270)

  • 1. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
    Stephan C; Jung K; Diamandis EP; Rittenhouse HG; Lein M; Loening SA
    Urology; 2002 Jan; 59(1):2-8. PubMed ID: 11796270
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostatic markers, today and tomorrow].
    Terrone C; Faraone N; Aimo G; Priolo G
    Recenti Prog Med; 2000 Nov; 91(11):576-80. PubMed ID: 11125951
    [No Abstract]   [Full Text] [Related]  

  • 3. Free/total prostate-specific antigen ratio--hope and controversies.
    Ravery V; Boccon-Gibod L
    Eur Urol; 1997; 31(4):385-8. PubMed ID: 9187894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum.
    Lilja H; Cockett AT; Abrahamsson PA
    Cancer; 1992 Jul; 70(1 Suppl):230-4. PubMed ID: 1376193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
    Tanaka M; Suzuki Y; Takaoka K; Murakami S; Suzuki N; Shimazaki J
    Int J Urol; 1999 Dec; 6(12):600-6. PubMed ID: 10609542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
    Grond A
    Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen: advances and challenges.
    Chan DW; Sokoll LJ
    Clin Chem; 1999 Jun; 45(6 Pt 1):755-6. PubMed ID: 10351982
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of complexes between prostate-specific antigen and protease inhibitors in plasma.
    Stenman UH
    Clin Chem; 2010 Dec; 56(12):1895-6. PubMed ID: 20940331
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
    Ansong K
    Urology; 1994 Aug; 44(2):296-7. PubMed ID: 7519383
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
    Wilson MJ
    J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
    [No Abstract]   [Full Text] [Related]  

  • 12. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein].
    Recker F; Kwiatowski MK; Piironen T
    Urologe A; 1998 Jul; 37(4):421-3. PubMed ID: 9738296
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
    Jain S; Bhojwani AG; Mellon JK
    Postgrad Med J; 2002 Nov; 78(925):646-50. PubMed ID: 12496317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging.
    Lee CT; Oesterling JE
    Semin Surg Oncol; 1995; 11(1):23-35. PubMed ID: 7538692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can expressed prostatic secretions effect prostate biopsy decision of urologist?
    Ergun O; Capar E; Goger YE; Ergun AG
    Int Braz J Urol; 2019; 45(2):246-252. PubMed ID: 30648827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
    Chen YB; Fine SW; Epstein JI
    Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
    Christensson A; Björk T; Nilsson O; Dahlén U; Matikainen MT; Cockett AT; Abrahamsson PA; Lilja H
    J Urol; 1993 Jul; 150(1):100-5. PubMed ID: 7685416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathological features of prostate basal cell lesions].
    Wang GW; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):483-6. PubMed ID: 24246874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.